ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease ECMOCARD study is an multi-centre International study, conducted in all collaborating hospitals/ICU-based research networks in Asia, Australia & New Zealand (APELSO in collaboration with centres within the SPRINT-SARI and ISARIC Networks), and Europe, in COVID-19 patients requiringadmission to to ICU, Mechanical Ventilation &/or ECMO, to characterize:
incidence of ICU admission, need for non-invasive/invasive MV and ECMO
risk factors, clinical features and severity of respiratory failure
ECMO technical characteristics & duration of the run
complications and ICU/Hospital survival
requirements/time for approvals in participating network regions.
Aim is to recruit all eligible patients at each study location; patients will be studied specifically focusing on collecting data on MV, ECMO, main therapies (includinvasoactives, hypoxaemia rescue therapies, RRT), antibiotics/antivirals, adjunctive therapies, ie immunomodulators, corticosteroids, short-term outcomes.
Laboratory-confirmed COVID-19 infection by real-time PCR and/or next-generation sequencing
Admission to an ICU
MV for other concomitant causes
ECMO for other concomitant causes
Family of RNA viruses which may infect mammals and birds, with 6 species known to cause human disease; 2 strains, the severe acute respiratory syndrome coronavirus SARS-CoV and Middle East respiratory syndrome coronavirus MERS-CoV have caused more serious, sometimes fatal, respiratory illnesses (reported mortality respectively 10% & 37%).
SARS-CoV-2 & COVID-19
In late December, 2019, in Wuhan, Hubei, China, new respiratory syndrome emerged with clinical signs resembling viral pneumonia and person-to-person transmission; analysis from lower respiratory tract samples corroborated emergence of novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 SARS–CoV-2, causing COrona VIrus Disease 2019 (COVID-19).